Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. - Wikidata - awgldk - TriplyDB

Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.

Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.

http://www.wikidata.org/entity/Q33418199

about

Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue.

P2860

Q41995034-AE9820A7-224E-4FF0-A69C-A22E35D0BC9A

P2860

Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.

http://www.wikidata.org/entity/Q33418199

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@ast

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@en

type

label

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@ast

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@en

prefLabel

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@ast

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@en

P1433

Q33418199-9A9B3B32-FC73-4EE3-966D-4487D0319D3C

P1476

Q33418199-9D135059-3F6B-4D83-8D7D-8D2343FACAD0

P2093

Q33418199-207D2455-DD71-42A8-B7FC-46111ED478C1

Q33418199-27718BFA-6CB1-4457-9D43-E8CD36626BB9

Q33418199-336B5224-BBE3-4162-BAE0-2938844C869A

Q33418199-631C35FA-1F68-4058-BE63-BA42F013DA7D

Q33418199-8F73D650-2666-46B2-8633-067ECFECE97E

Q33418199-A9FD371A-C859-4FAC-B401-6E03ED63C97E

Q33418199-BE57D64F-149A-4BD3-B061-30297E50768F

Q33418199-C63B9731-CE1A-412C-854E-32D590DC2A9A

Q33418199-E32BE028-EE78-49B0-8651-13456B4D500D

Q33418199-F2D1C047-89C9-4E02-8773-45A05F32C0FD

P2860

Q33418199-00D4E987-E1FF-4C60-9050-166EA7691872

Q33418199-0343F8CE-1282-4D30-A299-71284D399915

Q33418199-401B15BC-BEBB-4BEF-8BCA-3B62D23C0032

Q33418199-4C20F453-3E30-4778-A021-42EB178637BC

Q33418199-4F16F4EA-20CC-4C16-B062-42DBA79C5E29

Q33418199-5080C78D-9852-41DF-9A38-206A9B240937

Q33418199-55DBB3E8-BA6A-47E6-961E-70D26A45D58A

Q33418199-5A63CF29-CAAD-4336-BD33-C135A03F2815

Q33418199-5EB6922E-21A1-4BB6-95C8-BD41171635C5

Q33418199-6524F70A-D29A-43D0-B37A-D5F87FF446A0

P304

Q33418199-AB260CCC-2473-400E-AE23-6EB3E13A06EC

P31

Q33418199-A93CC873-6579-4F0E-A233-C1FA20D43A74

P356

Q33418199-F706AB42-3C28-4E87-9797-5AA3D5C555DA

P433

Q33418199-985E8159-0003-4323-BC74-9EEF69D72D7D

P478

Q33418199-4FA91DB2-3FA6-4F6B-9BD8-C21D197D02A4

P577

Q33418199-67E47841-D296-439C-A946-6B91DF46319C

P698

Q33418199-9E4686F4-2857-4B2E-B249-6F477B976197

P356

10428194.2014.975801

P1433

Leukemia & Lymphoma

P1476

Phase II study of (90)Y Ibritu ...... reated marginal zone lymphoma.

@en

P2093

Aldo N Serafini

http://www.w3.org/2001/XMLSchema#string

Alexandra Stefanovic

http://www.w3.org/2001/XMLSchema#string

Deborah Goodman

http://www.w3.org/2001/XMLSchema#string

Feng Miao

http://www.w3.org/2001/XMLSchema#string

Izidore S Lossos

http://www.w3.org/2001/XMLSchema#string

James E Hoffman

http://www.w3.org/2001/XMLSchema#string

Jesus C Fabregas

http://www.w3.org/2001/XMLSchema#string

Joseph D Rosenblatt

http://www.w3.org/2001/XMLSchema#string

Peter J Hosein

http://www.w3.org/2001/XMLSchema#string

Tulay Koru-Sengul

http://www.w3.org/2001/XMLSchema#string

P2860

Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie.

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.

P304

1750-1755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2014.975801

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25315074

http://www.w3.org/2001/XMLSchema#string